Biotin-Linked Polyclonal Antibody to Osteoglycin (OGN) Rattus norvegicus (Rat) Labelled antibody

OIF; SLRR3A; Mimecan Proteoglycan; Osteoinductive Factor

Add to Cart Distributors
Overview
Properties
  • SourceAntibody labeling
  • Ig Type IgG, Potency n/a
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelBiotin
  • Original Antibody n/a
  • Buffer FormulationPBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
  • TraitsLiquid, Concentration 500µg/mL
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Biotin-Linked Polyclonal Antibody to Osteoglycin (OGN) Packages (Simulation)
  • Biotin-Linked Polyclonal Antibody to Osteoglycin (OGN) Packages (Simulation)
  • Biotin-Linked Polyclonal Antibody to Osteoglycin (OGN) Western Blot; Sample: Rat Lung lysate
    Primary Ab: 0.2μg/ml Biotin-Linked Polyclonal Antibody to Osteoglycin (OGN)
    Second Ab: 0.2μg/ml HRP-Labeled Streptavidin (Catalog: IS089)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a rabbit polyclonal antibody raised against OGN. It has been selected for its ability to recognize OGN in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.2-2µg/mL;1:250-2500
Immunohistochemistry: 5-20µg/mL;1:25-100
Immunocytochemistry: 5-20µg/mL;1:25-100
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus.pubmed:27836731
  • Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease.pubmed:28824047
  • Osteoglycin, a novel coordinator of bone and glucose homeostasisPubmed:29799418
  • Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathwayPubmed:29499765
  • Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patientsPubmed:29867136
  • Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose TissuePubmed: 30332637
  • Osteoglycin across the adult lifespan34850904

Recommend products